Skip to main content

Table 2 Evolution of RA patients’ disease activity during the 24-months follow-up

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 Day 0W6M3M6M9M12M18M24
P1DAS 281.763.142.432.431.761.555.181.64
RTI46666886
Dose44444444
P2DAS 281.692.352.792.892.693.141.342.13
RTI46686844
Dose88888888
P3DAS 282.42.072.573.922.143.73.682.61
RTI46684454
Dose88888888
P4DAS 282.61.421.341.941.051.123.351.49
RTI46884555
Dose88888888
P5DAS 282.582.61.612.112.232.222.030.91
RTI46678899
Dose88888888
P6DAS 280.48NA0.761.370.280.282.221.84
RTI46766689
Dose88888888
P 7DAS 281.61NA2.571.341.943.2822.5
RTI45888888
Dose68866688
P8DAS 281.982.261.682.14NA1.812.42Secondary failure Switch to infliximab
RTI4668884
Dose8888884
P9DAS 280.071.451.891.891.120.760.761.12
RTI466778910
Dose88888888
P10DAS 281.383.2NA2.852.453.71Secondary failure Switch to abatacept
RTI464444
Dose888888
P11DAS 282.312.313.480.85Neutropenia
Switch to abatacept
RTI4564
Dose4466
P12DAS 282.561.034.083.51Secondary failure
Switch to abatacept
RTI4664
Dose8888
P13DAS 2801.031.552.575.35Secondary failure
Switch to abatacept
RTI46686
Dose66666
  1. Dose mg/kg, W week, M month, P patient, RTI retreatment interval, NA not available